Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;35(3):209-21.
doi: 10.1097/PGP.0000000000000251.

Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience

Sandra Lee  1 , Anna M Piskorz, Cécile Le Page, Anne-Marie Mes Masson, Diane Provencher, David Huntsman, Wenqian Chen, Paul E Swanson, C Blake Gilks, Martin Köbel
Affiliations

Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience

Sandra Lee et al. Int J Gynecol Pathol. 2016 May.

Abstract

The Canadian Immunohistochemistry Quality Control provides proficiency testing for immunohistochemistry in Canadian laboratories. Canadian Immunohistochemistry Quality Control Run 42 assessed WT1, Napsin A, and p53; commonly used markers for histotyping ovarian carcinomas. A 42-core tissue microarray, which included the 5 major histotypes of ovarian carcinomas with a subset having known TP53 mutational status, was used for this Canadian Immunohistochemistry Quality Control challenge. Participants included 43 laboratories for p53, 29 for WT1, and 26 for Napsin A. p53 was scored as aberrant if the staining was strong and diffuse or absent. Napsin A and WT1 were scored positive if any tumor cells stained. The reference p53 expression pattern was inferred by TP53 mutation type when available. For WT1, Napsin A, and cases lacking mutational data, the reference staining pattern was based on the majority staining result. The error rate for p53 was 8.8%. Most errors (84%) were due to weak staining. The sensitivity and specificity of aberrant p53 expression for an underlying TP53 mutation was 91.6% and 87.9%, respectively. The error rate for WT1 was 0.76% with all errors occurring in laboratories using the 6F-h2 clone. The average errors for laboratories using 6F-h2 were 2.4 compared with 0 for WT-49. The error rate for Napsin A was 4%. The average errors for laboratories using polyclonal Napsin A were 3 compared with 1.1 for monoclonal Napsin A. Weak p53 staining increases interpretative errors, primarily due to absence of staining in tumors with wild-type TP53. p53 immunohistochemistry correlates strongly with TP53 mutational status. Polyclonal Napsin A and 6F-h2 may lack specificity in comparison to monoclonal Napsin A and WT-49.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Napsin A Expression in Human Tumors and Normal Tissues.
    Weidemann S, Böhle JL, Contreras H, Luebke AM, Kluth M, Büscheck F, Hube-Magg C, Höflmayer D, Möller K, Fraune C, Bernreuther C, Rink M, Simon R, Menz A, Hinsch A, Lebok P, Clauditz T, Sauter G, Uhlig R, Wilczak W, Steurer S, Burandt E, Krech R, Dum D, Krech T, Marx A, Minner S. Weidemann S, et al. Pathol Oncol Res. 2021 Apr 20;27:613099. doi: 10.3389/pore.2021.613099. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34257582 Free PMC article.
  • Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM. Le Page C, et al. BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8. BMC Cancer. 2018. PMID: 29587661 Free PMC article.
  • An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.
    Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, de Ladurantaye M, Lee S, Leung S, Goode EL, Ramus SJ, Carlson JW, Li X, Ewanowich CA, Kelemen LE, Vanderhyden B, Provencher D, Huntsman D, Lee CH, Gilks CB, Mes Masson AM. Köbel M, et al. Int J Gynecol Pathol. 2016 Sep;35(5):430-41. doi: 10.1097/PGP.0000000000000274. Int J Gynecol Pathol. 2016. PMID: 26974996 Free PMC article.
  • Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.
    Momeni-Boroujeni A, Dahoud W, Vanderbilt CM, Chiang S, Murali R, Rios-Doria EV, Alektiar KM, Aghajanian C, Abu-Rustum NR, Ladanyi M, Ellenson LH, Weigelt B, Soslow RA. Momeni-Boroujeni A, et al. Clin Cancer Res. 2021 May 1;27(9):2613-2623. doi: 10.1158/1078-0432.CCR-20-4436. Epub 2021 Feb 18. Clin Cancer Res. 2021. PMID: 33602681 Free PMC article.
  • Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.
    Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD. Köbel M, et al. J Pathol Clin Res. 2016 Jul 13;2(4):247-258. doi: 10.1002/cjp2.53. eCollection 2016 Oct. J Pathol Clin Res. 2016. PMID: 27840695 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources